Document is current
Any future updates will be listed below
-
Authors
Karnieg, Taleen https://orcid.org/0000-0002-5317-7964
Vincent, Maurice https://orcid.org/0000-0001-5855-6069
Martinez, James https://orcid.org/0009-0000-6908-6269
Whitton, William https://orcid.org/0009-0004-8342-2125
Hargreaves, Lucy https://orcid.org/0009-0000-7925-8175
Papadimitropoulos, Emmanuel https://orcid.org/0000-0002-3688-523X
-
Funding
Funding for this research was provided by:
Eli Lilly Canada
- License Information
-
More Information
Article History
Received: 4 September 2025
Accepted: 30 October 2025
First Online: 3 December 2025
Declarations
:
: Taleen Karnieg: No conflicts to declare. Maurice Vincent, James Martinez, and Emmanuel Papadimitropoulos were employees of Eli Lilly & Company at the time the research was conducted and manuscript written, and own shares/stock in Eli Lilly & Company. Lucy Hancock and William Whitton are employees of Adelphi Real World.
: The Adelphi Real World CH Disease Specific Programme (DSP)™ is a market research study conducted under the European Pharmaceutical Market Research Association (EphMRA) Code of Conduct, which states, “Market Research relating to market or consumer behaviour of the sort that pharmaceutical companies routinely commission, whether involving healthcare professionals, patients, carers or members of the public, does not require Clinical Research Ethics Committee approval,” and as such it did not require ethics committee approval [ ]. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Declaration of Helsinki (1964) and its later amendments. This research was submitted to the Pearl Institutional Review Board, and a waiver was obtained. Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly [ ].
